GYRE - Gyre Therapeutics Inc
IEX Last Trade
13.385
-0.345 -2.578%
Share volume: 32,987
Last Updated: Fri 30 Aug 2024 07:58:15 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$13.73
-0.35
-2.51%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-15 | 2022-11-14 | 2023-03-30 | 2023-05-15 | 2023-08-14 | 2023-10-26 | 2024-03-27 | 2024-05-13 | |
| Assets | |||||||||
| Total Assets | 83.373 M | 31.019 M | 28.444 M | 18.750 M | 12.394 M | 9.964 M | 116.539 M | 122.010 M | |
| Current Assets | 81.308 M | 30.246 M | 28.206 M | 14.014 M | 7.620 M | 5.132 M | 57.221 M | 62.723 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 4.281 M | 4.939 M | |
| Other Current Assets | 914.000 K | 2.156 M | 1.540 M | 915.000 K | 697.000 K | 1.704 M | 2.592 M | 11.254 M | |
| Short Term Investments | 914.000 K | 2.156 M | 1.540 M | 915.000 K | 697.000 K | 1.704 M | 2.592 M | 11.254 M | |
| Total Receivables | 5.000 M | 5.000 M | 5.000 M | 5.000 M | 0.000 | 1.200 M | 16.839 M | 16.745 M | |
| Current Cash | 75.394 M | 23.090 M | 21.666 M | 8.099 M | 6.923 M | 2.228 M | 33.509 M | 29.785 M | |
| Total Non-current Assets | 2.065 M | 773.000 K | 238.000 K | 4.736 M | 4.774 M | 4.832 M | 59.318 M | 59.287 M | |
| Property Plant Equipment | 164.000 K | 124.000 K | 4.000 K | 1.000 K | 0.000 | 0.000 | 23.288 M | 23.564 M | |
| Other Assets | 168.000 K | 168.000 K | 168.000 K | 4.718 M | 4.774 M | 4.832 M | 29.148 M | 28.688 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 1.698 M | 1.676 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 83.373 M | 31.019 M | 28.444 M | 18.750 M | 12.394 M | 9.964 M | 116.539 M | 122.010 M | |
| Total liabilities | 4.311 M | 1.644 M | 16.824 M | 11.394 M | 7.399 M | 6.447 M | 67.842 M | 65.370 M | |
| Total current liabilities | 4.311 M | 1.644 M | 16.824 M | 6.844 M | 2.793 M | 1.783 M | 20.047 M | 19.486 M | |
| Accounts Payable | 1.037 M | 41.000 K | 7.752 M | 16.000 K | 5.000 K | 158.000 K | 355.000 K | 330.000 K | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 4.550 M | 4.606 M | 4.664 M | 17.819 M | 13.578 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 4.550 M | 4.606 M | 4.664 M | 17.819 M | 13.578 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 29.777 M | 32.131 M | |
| Total Shareholder equity | 79.062 M | 29.375 M | 11.620 M | 7.356 M | 4.995 M | 3.517 M | 48.697 M | 56.640 M | |
| Common stock | 31.477 M | 31.485 M | 31.765 M | 37.758 M | 37.800 M | 37.977 M | 149.791 M | 83.266 M | |
| Retained earnings | -365.598 M | -370.482 M | -410.936 M | -410.676 M | -413.148 M | -414.724 M | -85.538 M | -78.006 M |